1342.1 - Oncotype DX breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)

Page last updated: 11 July 2016

Application Detail



Description of Medical Service

Oncotype DX is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.

Description of Medical Condition

Outside Australia, Oncotype DX is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.

Reason for Application

New MBS item

Medical Service Type


Previous Application Number


Associated Documentation

Application Form


PICO Confirmation

Please see Application 1342

Assessment Report


Public Summary Document

Public Summary Document (PDF 58 KB)
Public Summary Document (Word 143 KB)

Meetings for this Application




13 -14 February 2014


3 - 4 April 2014